Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc.
Bullboard Posts
User Avatar Image
(239)
•••
Comment by made2laston Sep 28, 2018 11:59am
77 Views
Post# 28709852

RE:RE:RE:RE:RE:Reversing the Warburg Effect is a very big deal

RE:RE:RE:RE:RE:Reversing the Warburg Effect is a very big dealHi fred;

At the very least, Sigma-Aldrich can extract and provide concentrated human transferrin from the patients own blood plasma. Why not consider that possibility, until a synthetic could be considered?

https://www.sigmaaldrich.com/catalog/product/sigma/90190?lang=en&region=US

Thanks;

made2last


fredgoodwinson wrote: No we don`t know that Hankerchief and I would guess not.

Apart from being told a lot of its`advantages over TLD-1433 and its`good results in preclinical experiments against major cancers we haven`t been told much of the status of the drug and whether it might be used in humans. There is apparently safe synthetic transferrin (Optiferrin) which would address prion and virus concerns so given that it is less toxic as well as more effective than TLD-1433 it is surprising that it has not advanced to at least approval in principle and given that this is a simple incubation with transferrin of a complex compound (TLD-1433) you`d have thought that it would have been given the green light in humans by now.


Bullboard Posts
Dealroom for high-potential pre-IPO opportunities